All filters
Slidesets
Rifampin vs. Rifapentine: a debate over the preferred rifamycin | Kelly Dooley, MD, PhD
Presented at:
International Workshop on Clinical Pharmacology of Tuberculosis Drugs 2016
Slidesets
Pharmacokinetic Modeling and Simulation of the Interaction between Moxifloxacin and Rifapentine in Healthy Volunteers | M. Imperial
Presented at:
International Workshop on Clinical Pharmacology of Tuberculosis Drugs 2016
Slidesets
Lung Tissue Concentrations of Pyrazinamide among Patients with Tuberculosis | R. Kempker
Presented at:
International Workshop on Clinical Pharmacology of Tuberculosis Drugs 2016
Slidesets
Rifampin vs. Rifapentine: a debate over the preferred rifamycin | Charles Peloquin, PharmD
Presented at:
International Workshop on Clinical Pharmacology of Tuberculosis Drugs 2016
Slidesets
Early interventions for diabetes related tuberculosis hasten sputum microbiological clearance in Virginia, USA | S. Heysell
Presented at:
International Workshop on Clinical Pharmacology of Tuberculosis Drugs 2016
Slidesets
Sub-therapeutic concentrations of anti-tuberculosis drugs in children when treated according to indian dosing recommendation | B. Guiastrennec
Presented at:
International Workshop on Clinical Pharmacology of Tuberculosis Drugs 2016
Slidesets
A Need for altering Tuberculosis Dosing Regiments for patients with HIV-associated Tuberculous Meningitis | G. Aljayyoussi
Presented at:
International Workshop on Clinical Pharmacology of Tuberculosis Drugs 2016
Slidesets
Lost in translation: learning from preclinical data | Gerry Davies
Presented at:
International Workshop on Clinical Pharmacology of Tuberculosis Drugs 2016
Slidesets
Application Of A Multi-Compartment Permeability-Limited Lung Model To Predict Lung Concentrations Of Moxifloxacin In Virtual Human Subjects | O. Hatley
Presented at:
International Workshop on Clinical Pharmacology of Tuberculosis Drugs 2016
Slidesets
A translational modelling and simulations approach to exploit pre-clinical tuberculosis data | S. Wicha
Presented at:
International Workshop on Clinical Pharmacology of Tuberculosis Drugs 2016
Slidesets
Simulation of long-acting administration of antituberculosis agents using pharmacokinetic modelling | R. Rajoli
Presented at:
International Workshop on Clinical Pharmacology of Tuberculosis Drugs 2016
Slidesets
Long acting (LA) drug delivery in TB treatment | Andrew Owen, BSS, MSC, PhD, FSB
Presented at:
International Workshop on Clinical Pharmacology of Tuberculosis Drugs 2016
Slidesets
Rifapentine plus Isoniazid Eradicates Mycobacterium tuberculosis among Rhesus Macaques with Latent TB Infection | H. Blumberg
Presented at:
International Workshop on Clinical Pharmacology of Tuberculosis Drugs 2016
Slidesets
High drug tolerance of Mycobacterium tuberculosis in caseum | J. Sarathy
Presented at:
International Workshop on Clinical Pharmacology of Tuberculosis Drugs 2016
Slidesets
Exploration of Non-Replicating Mycobacterium Tuberculosis In Vitro System Through Mathematical Modelling | A. Schipani
Presented at:
International Workshop on Clinical Pharmacology of Tuberculosis Drugs 2016
Slidesets
A model-based analysis to describe bedaquiline’s exposure-response relationship and predict the impact of drug-drug interactions | E. Svensson
Presented at:
International Workshop on Clinical Pharmacology of Tuberculosis Drugs 2016
Slidesets
A new model for early clinical development of TB drugs and its application to Q203 and BTZ043 | Norbert Heinrich, MD
Presented at:
International Workshop on Clinical Pharmacology of Tuberculosis Drugs 2016
Slidesets
Population Pharmacokinetics of AZD5847 in Adults with Pulmonary Tuberculosis | C. Peloquin
Presented at:
International Workshop on Clinical Pharmacology of Tuberculosis Drugs 2016
Slidesets
Population pharmacokinetic modeling to assess the non-linear increase in exposure following increasing doses of rifampicin | R. Svensson
Presented at:
International Workshop on Clinical Pharmacology of Tuberculosis Drugs 2016